The U.S. Food and Drug Administration (FDA) in late March approved the biologic medication certolizumab pegol (Cimzia), a tumor necrosis factor (TNF) inhibitor, to treat a newly defined condition called non-radiographic axial spondyloarthritis (nr-axSpA). Continue reading FDA Approves First Drug for Newly Defined Spinal Condition
If you have gout and rely on lesinurad (Zurampic) or lesinurad plus allopurinol (Duzallo), you’ll need to check with your doctor to find an alternative for managing the pain, swelling, redness and other symptoms of your disease. That’s because these two drugs have been pulled from the market. Continue reading Two Gout Drugs Removed From Market
If you have arthritis, chances are your doctor gave you a prescription for an opioid pain medication at some point. Opioids are effective at relieving pain, including post-surgical pain, and for some people who live with chronic pain from arthritis or other conditions, they are one part of managing that condition.
Personalized treatments for children with arthritis will soon be a reality, thanks to a new research study supported by the Arthritis Foundation.
The study, the largest of its kind, is being done by the Childhood Arthritis and Rheumatology Research Alliance (CARRA), a North American research network that conducts collaborative research to find treatments and a cure for pediatric rheumatic diseases. The Arthritis Foundation has worked closely with CARRA since it was formed in 2002. Together, we’ve aligned our scientific agendas, and the Foundation has committed millions of dollars toward expanding juvenile arthritis research through CARRA.
More than 15,000 doctors, nurses, physical therapists, researchers, scientists and others with interest and/or expertise in rheumatology gathered in Chicago in late October for the American College of Rheumatology’s Annual Meeting. The Arthritis Foundation had a contingent of “patient representatives” attending to provide the perspective and voice of people living with arthritis. They fanned out to attend sessions, view and present posters and collect information about exciting new developments in the field. Here are their notes from the final sessions of the meeting.
Physical exercise is recommended as the first approach for relief of arthritis symptoms, yet many people do not participate in regular physical activity. New research suggests that doctors and other health care professionals who treat people with arthritis are doing a better job at counseling them on physical exercise, but there is still plenty of room for improvement.
A study published recently by the Centers for Disease Control and Prevention (CDC) found that the number of people with arthritis who said they were counseled by a health care professional about doing exercise to improve arthritis symptoms increased by 18 percent between 2002 and 2014, from 52 percent to 61 percent. But that means that approximately 40 percent of people with arthritis who seek medical care still are not getting appropriate counseling at their medical visits. The findings appeared in the Morbidity and Mortality Weekly Report (MMWR), published by the CDC.
Biotech giant Sanofi Genzyme has initiated a voluntary product recall for one lot of Synvisc-One, a brand of hyaluronic acid. The lot, which was found to contain contamination, has been linked to an unexpected increase in side effects. In an urgent “product hold” letter, doctors, clinics and pharmacies who received syringes from that lot were instructed to immediately stop using the injections on patients until the company can investigate.
Continue reading Synvisc-One Injections Recalled
Ninety percent of people in the United States who have the chronic autoimmune disease lupus are women and, according to two new studies published recently in Arthritis & Rheumatology, large proportions are Hispanic or Asian. Like African-Americans, these two ethnic/racial groups are not only at higher risk of lupus than whites, they’re also more likely to have aggressive forms of the disease, researchers in New York and San Francisco found.
Lupus, or systemic lupus erythematosus (SLE), an affect virtually every organ system, and symptoms vary widely. Some patients have relatively mild skin and joint symptoms that may go into remission for long periods. Others have cognitive (neuropsychiatric) manifestations or life-threatening complications such as lung, heart and kidney problems.
A big study published in 2016, called the PRECISION trial, found that people with arthritis who take the anti-inflammatory drug ibuprofen are more likely to develop cardiovascular problems than those using celecoxib – and now researchers think they know why. Ibuprofen raises blood pressure, according to new findings presented recently at the annual meeting of the European Society of Cardiology in Barcelona.
The number of biosimilars approved by the Food and Drug Administration (FDA) continues to grow in the United States, and they are slowly becoming available to consumers.
In late August, the FDA approved Cyltezo (adalimumab-adbm), a second biosimilar to Humira (adalimumab). But like the first biosimilar, Amjevita (adalimumab-atto), which was approved in September 2016, it is not yet available to U.S. consumers because of pending patent litigation with AbbVie, the manufacturer of Humira.